Patents by Inventor Martine Van Vugt

Martine Van Vugt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-OX40L antibodies
    Publication number: 20100166740
    Abstract: This invention relates to anti-OX40L antibodies and, in particular, to anti-OX40L antibodies and variants thereof that contain a Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from inflammatory diseases.
    Type: Application
    Filed: December 5, 2008
    Publication date: July 1, 2010
    Inventors: Joseph Endl, Elsie M. Eugui, Maria Elena Fuentes, Yvo Graus, Aran Frank Labrijn, Martin Lanzendoerfer, Paul Parren, Frank Rebers, Ralf Schumacher, Stefan Seeber, Jan Van de Winkel, Martine Van Vugt
  • COMBINATION TREATMENT OF CD38-EXPRESSING TUMORS
    Publication number: 20100092489
    Abstract: The invention relates to novel method for the treatment of cancer using a combination therapy comprising an antibody that binds CD38, a corticosteroid and a non- corticosteroid chemotherapeutic agent.
    Type: Application
    Filed: September 26, 2007
    Publication date: April 15, 2010
    Applicant: GENMAB A/S
    Inventors: Jan Van De Winkel, Paul Parren, Yvo Graus, Judith Oprins, Michel De Weers, Martine Van Vugt, Ole Baadsgaard, Steen Lisby
  • ANTI-P-SELECTIN ANTIBODIES
    Publication number: 20090311779
    Abstract: This invention relates to anti-P-selectin antibodies and, in particular, to anti-P-selectin antibodies and variants thereof that contain an Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from critical limb ischemia or peripheral arterial occlusive disease (CLI/PAOD).
    Type: Application
    Filed: June 10, 2009
    Publication date: December 17, 2009
    Inventors: Yvo Graus, Jacques Himber, Miranda Jansen-Molenaar, Dorothee Kling, Erhard Kopetzki, Paul Parren, Frank Rebers, Beat Steiner, Anne Stern, Pamela Strein, Kay-Gunnar Stubenrauch, Jan van de Winkel, Martine van Vugt
  • Anti-P-selectin antibodies
    Patent number: 7563441
    Abstract: This invention relates to anti-P-selectin antibodies and, in particular, to anti-P-selectin antibodies and variants thereof that contain an Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from critical limb ischemia or peripheral arterial occlusive disease (CLI/PAOD).
    Type: Grant
    Filed: April 8, 2005
    Date of Patent: July 21, 2009
    Assignee: Hoffman-La Roche Inc.
    Inventors: Yvo Graus, Jacques Himber, Miranda Jansen-Molenaar, Dorothee Kling, Erhard Kopetzki, Paul Parren, Frank Rebers, Beat Steiner, Anne Stern, Pamela Strein, Kay-Gunnar Stubenrauch, Jan van de Winkel, Martine van Vugt
  • Antibodies against cd38 for treatment of multiple myeloma
    Publication number: 20090148449
    Abstract: Isolated human monoclonal antibodies which bind to human CD38, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
    Type: Application
    Filed: March 23, 2006
    Publication date: June 11, 2009
    Applicant: Genmab A/S
    Inventors: Michel De Weers, Yvo Graus, Judith Oprins, Paul Parren, Jan Van De Winkel, Martine Van Vugt
  • Antibodies against CD38 for treatment of multiple myeloma
    Publication number: 20090076249
    Abstract: Isolated human monoclonal antibodies which bind to human CD38, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
    Type: Application
    Filed: September 19, 2007
    Publication date: March 19, 2009
    Inventors: Michel De Weers, Yvo Graus, Judith Oprins, Paul Parren, Jan Van De Winkel, Martine Van Vugt
  • Anti-OX40L antibodies
    Patent number: 7501496
    Abstract: This invention relates to anti-OX40L antibodies and, in particular, to anti-OX40L antibodies and variants thereof that contain a Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from inflammatory diseases.
    Type: Grant
    Filed: September 16, 2005
    Date of Patent: March 10, 2009
    Assignee: Roche Palo Alto LLC
    Inventors: Joseph Endl, Elsie M. Eugui, Maria Elena Fuentes, Yvo Graus, Aran Frank Labrijn, Martin Lanzendoerfer, Paul Parren, Frank Rebers, Ralf Schumacher, Stefan Seeber, Jan Van De Winkel, Martine Van Vugt
  • Antibodies against IL-13 receptor alpha1 and uses thereof
    Publication number: 20060263356
    Abstract: An antibody binding to IL-13R?1, inhibiting IL-13 bioactivity and comprising a variable heavy and a variable light chain, characterized in that the variable heavy chain amino acid sequence CDR3 of said antibody is selected from the group consisting of the heavy chain CDR3 sequences of SEQ ID NO: 1, 3, 5, 7 or 9 is useful in the treatment of asthma and allergic diseases.
    Type: Application
    Filed: January 3, 2006
    Publication date: November 23, 2006
    Inventors: Josef Endl, Maria Fuentes, Yvo Graus, Adelbert Grossmann, Sebastian Neumann, Paul Parren, Frank Rebers, Joerg Regula, Ralf Schumacher, Stefan Seeber, Jan stracke, Kay-Gunnar Stubenrauch, Jan Van De Winkel, Martine Van Vugt, Sandra Vereecken-Verploegen
  • Anti-P-selectin antibodies
    Publication number: 20050226876
    Abstract: This invention relates to anti-P-selectin antibodies and, in particular, to anti-P-selectin antibodies and variants thereof that contain an Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from critical limb ischemia or peripheral arterial occlusive disease (CLI/PAOD).
    Type: Application
    Filed: April 8, 2005
    Publication date: October 13, 2005
    Inventors: Yvo Graus, Jacques Himber, Miranda Jansen-Molenaar, Dorothee Kling, Erhard Kopetzki, Paul Parren, Frank Rebers, Beat Steiner, Anne Stern, Pamela Strein, Kay-Gunnar Stubenrauch, Jan van de Winkel, Martine van Vugt